Compare NBHC & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBHC | NRIX |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2011 | 2020 |
| Metric | NBHC | NRIX |
|---|---|---|
| Price | $39.65 | $15.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $45.33 | $29.46 |
| AVG Volume (30 Days) | 464.5K | ★ 694.1K |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.85 | N/A |
| Revenue | $47,100,000.00 | ★ $76,987,000.00 |
| Revenue This Year | $39.32 | N/A |
| Revenue Next Year | $6.74 | $26.32 |
| P/E Ratio | $14.11 | ★ N/A |
| Revenue Growth | 2.86 | ★ 99.31 |
| 52 Week Low | $32.83 | $8.18 |
| 52 Week High | $42.99 | $22.50 |
| Indicator | NBHC | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 42.30 | 46.92 |
| Support Level | $37.79 | $15.62 |
| Resistance Level | $40.97 | $16.49 |
| Average True Range (ATR) | 1.13 | 0.78 |
| MACD | -0.19 | 0.05 |
| Stochastic Oscillator | 19.01 | 65.87 |
National Bank Holdings Corp is a bank holding company. It provides various banking products and financial services to commercial, business, and consumer clients in the United States. The company offers deposit products including checking accounts, savings accounts, money market accounts, and other deposit accounts, including fixed-rate and fixed-maturity time deposits. It also provides commercial and industrial loans and leases. In addition, it offers treasury management solutions comprising online and mobile banking, commercial credit cards, wire transfers, automated clearing house, and electronic bill payments.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.